Literature DB >> 28337265

Pulmonary surfactant synthesis in miRNA-26a-1/miRNA-26a-2 double knockout mice generated using the CRISPR/Cas9 system.

Ying-Hui Zhang1, Li-Zhi Wu1, Hong-Lu Liang1, Yang Yang1, Jie Qiu1, Qing Kan1, Wen Zhu1, Cheng-Ling Ma1, Xiao-Yu Zhou1.   

Abstract

Pulmonary surfactant (PS), which is synthesized by type II alveolar epithelial cells (AECIIs), maintains alveolar integrity by reducing surface tension. Many premature neonates who lack adequate PS are predisposed to developing respiratory distress syndrome (RDS), one of the leading causes of neonatal morbidity and mortality. PS synthesis is influenced and regulated by various factors, including microRNAs. Previous in vitro studies have shown that PS synthesis is regulated by miR-26a in fetal rat AECIIs. This study aimed to investigate the role of miR-26a in PS synthesis in vivo. To obtain a miR-26a-1/miR-26a-2 double knockout mouse model, we used the clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) system, an important genome editing technology. Real-time PCR was performed to determine the miR-26a levels in various organs, as well as the mRNA levels of surfactant-associated proteins. Moreover, AECIIs and surfactant-associated proteins in lung tissues were analyzed by hematoxylin-eosin staining and immunohistochemistry. Homozygous offspring of miR-26a-1/miR-26a-2 double knockout mice generated using the CRISPR/Cas9 system were successfully obtained, and PS synthesis and the number of AECIIs were significantly increased in the miR-26a knockout mice. These results indicate that miR-26a plays an important role in PS synthesis in AECIIs.

Entities:  

Keywords:  AECII; CRISPR/Cas9; PS; knockout mice; miR-26a

Year:  2017        PMID: 28337265      PMCID: PMC5340672     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  38 in total

Review 1.  Hormonal regulation of pulmonary surfactant.

Authors:  P L Ballard
Journal:  Endocr Rev       Date:  1989-05       Impact factor: 19.871

Review 2.  Regulation of surfactant secretion in alveolar type II cells.

Authors:  Alexandra V Andreeva; Mikhail A Kutuzov; Tatyana A Voyno-Yasenetskaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-05-11       Impact factor: 5.464

Review 3.  An emerging role for the miR-26 family in cardiovascular disease.

Authors:  Basak Icli; Pranav Dorbala; Mark W Feinberg
Journal:  Trends Cardiovasc Med       Date:  2014-06-12       Impact factor: 6.677

Review 4.  MicroRNAs in development and disease.

Authors:  Danish Sayed; Maha Abdellatif
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

5.  Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.

Authors:  Yuyu Niu; Bin Shen; Yiqiang Cui; Yongchang Chen; Jianying Wang; Lei Wang; Yu Kang; Xiaoyang Zhao; Wei Si; Wei Li; Andy Peng Xiang; Jiankui Zhou; Xuejiang Guo; Ye Bi; Chenyang Si; Bian Hu; Guoying Dong; Hong Wang; Zuomin Zhou; Tianqing Li; Tao Tan; Xiuqiong Pu; Fang Wang; Shaohui Ji; Qi Zhou; Xingxu Huang; Weizhi Ji; Jiahao Sha
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

6.  MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN.

Authors:  Boning Liu; Xiang Wu; Bin Liu; Changli Wang; Yunde Liu; Qinghua Zhou; Ke Xu
Journal:  Biochim Biophys Acta       Date:  2012-08-04

7.  Maternally imprinted microRNAs are differentially expressed during mouse and human lung development.

Authors:  Andrew E Williams; Sterghios A Moschos; Mark M Perry; Peter J Barnes; Mark A Lindsay
Journal:  Dev Dyn       Date:  2007-02       Impact factor: 3.780

8.  Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids.

Authors:  Sterghios A Moschos; Andrew E Williams; Mark M Perry; Mark A Birrell; Maria G Belvisi; Mark A Lindsay
Journal:  BMC Genomics       Date:  2007-07-17       Impact factor: 3.969

Review 9.  Advances in microRNAs: implications for immunity and inflammatory diseases.

Authors:  E Sonkoly; A Pivarcsi
Journal:  J Cell Mol Med       Date:  2009-01       Impact factor: 5.310

10.  High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer.

Authors:  Petra Leidinger; Thomas Brefort; Christina Backes; Medea Krapp; Valentina Galata; Markus Beier; Jochen Kohlhaas; Hanno Huwer; Eckart Meese; Andreas Keller
Journal:  Oncotarget       Date:  2016-01-26
View more
  5 in total

1.  MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.

Authors:  Ryan J Good; Laura Hernandez-Lagunas; Ayed Allawzi; Joanne K Maltzahn; Christine U Vohwinkel; Arun K Upadhyay; Uday B Kompella; Konstantin G Birukov; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-07-19       Impact factor: 5.464

2.  CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function.

Authors:  Lazaros Lataniotis; Andreas Albrecht; Fatma O Kok; Clinton A L Monfries; Lorena Benedetti; Nathan D Lawson; Simon M Hughes; Kathleen Steinhofel; Manuel Mayr; Anna Zampetaki
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

Review 3.  In vivo genome editing thrives with diversified CRISPR technologies.

Authors:  Xun Ma; Avery Sum-Yu Wong; Hei-Yin Tam; Samuel Yung-Kin Tsui; Dittman Lai-Shun Chung; Bo Feng
Journal:  Zool Res       Date:  2018-03-18

4.  The role of miR-431-5p in regulating pulmonary surfactant expression in vitro.

Authors:  Shujun Li; Zhongyi Sun; Tao Chen; Jingjing Pan; Yanqing Shen; Xiaoqing Chen; Xiaoyu Zhou; Rui Cheng; Yang Yang
Journal:  Cell Mol Biol Lett       Date:  2019-04-02       Impact factor: 5.787

Review 5.  Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?

Authors:  Edibe Avci; Pouya Sarvari; Rajkumar Savai; Werner Seeger; Soni S Pullamsetti
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.